Bellicum Pharmaceuticals, Inc.
Bellicum Pharmaceuticals, Inc. (BLCM) Revenue
Annual & quarterly revenue history · segment & region breakdown
BLCM · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsBellicum Pharmaceuticals, Inc. trailing twelve-month (TTM) revenue is $0.00B, a decrease of 75.81% year-over-year from $0.00B in FY2022.
Revenue trend
2022 – 2012 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2022-12-31 | $0.00B | -$0.00B | -75.81% |
| 2021-12-31 | $0.01B | +$0.01B | +1140.00% |
| 2020-12-31 | $0.00B | -$0.01B | -93.00% |
| 2019-12-31 | $0.01B | +$0.01B | +537.77% |
| 2018-12-31 | $0.00B | +$0.00B | +505.41% |
| 2017-12-31 | $0.00B | -$0.00B | -52.32% |
| 2016-12-31 | $0.00B | +$0.00B | +37.59% |
| 2015-12-31 | $0.00B | -$0.00B | -84.16% |
| 2014-12-31 | $0.00B | -$0.00B | -8.28% |
| 2013-12-31 | $0.00B | +$0.00B | +31.99% |
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Bellicum Pharmaceuticals, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Bellicum Pharmaceuticals, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Bellicum Pharmaceuticals, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
BLCM revenue · 4 questionsBLCM's trailing twelve-month (TTM) revenue is $0.00B. That is a decrease of 75.81% year-over-year from $0.00B in FY2022.
▸ Source: FMP · Bellicum Pharmaceuticals, Inc. SEC filings · GAAP · Bellicum Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026